Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Indy Hematology Review

A. Tefferi

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Indy Hematology Review

A. Tefferi

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Indy Hematology Review

S. Smith

State of the Art in 2024: Emerging Therapies in Hematologic Malignan…

Indy Hematology Review

R. Birhiray

Treatment Strategies for Hematocrit Control in PV

Insights from 2023 ASH Annual Meeting

A. Zhou

Masterclasses from the Wards

Masterclasses in Dermatology

S. Elman

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

New Approval for Frontline Consolidation in Patients with CD19-posit…

Amgen Sponsorship

J. Mccloskey

Review of Myeloproliferative Neoplasms

Indy Hematology Review

A. Tefferi

Momelotinib for Myelofibrosis: Top 10 Things You Should Know Post-FD…

Ruben Mesa

Clinical Case Review: A Not-So-Sweet Case of Vulvar Ulceration

2024 Clinical Case Studies

A. Geisler

SIMPLIFY-2 Trial: Momelotinib Vs. Continued Ruxolitinib or Best Avai…

Cleveland Clinic Taussig Cancer Institute

A. Gerds

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Incyte

C. Harrison

Practice-Changing Abstracts in NHL and HL From ASH 2023

UChicago Medicine

S. Smith

Treatment Updates and Management of Non-Hodgkin Lymphomas

Integrity CE

D. Wallace, M. Cortese

ASCO® 2024 Summary: "Comparative Review of Toxicities and Their Mana…

2024 ASCO® Annual Meeting Insights Hub

M. Minnema

Practice-Changing Updates in DLBCL and HL

Massachusetts General Hospital Cancer Center

J. Erika Haydu

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Incyte

C. Harrison

Hematopathology Tumor Board: Case Studies and Diagnostic Challenges …

UChicago Medicine

G. Venkataraman, A. Perry, K. Cahill, A. Akmatbekov, L. Wu

2024 Updates on Myelofibrosis and Systemic Mastocytosis

Indy Hematology Review

R. Rampal